BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12380358)

  • 1. [Statins plus inhibition of cholesterol absorption. Dual mechanism of action in lipid therapy].
    MMW Fortschr Med; 2002 Sep; 144(35-36):51. PubMed ID: 12380358
    [No Abstract]   [Full Text] [Related]  

  • 2. [Statins plus cholesterol resorption inhibitor. LDL goal values attainable].
    MMW Fortschr Med; 2002 Sep; 144(38):56. PubMed ID: 12395708
    [No Abstract]   [Full Text] [Related]  

  • 3. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
    Feldman T; Koren M; Insull W; McKenney J; Schrott H; Lewin A; Shah S; Sidisin M; Cho M; Kush D; Mitchel Y
    Am J Cardiol; 2004 Jun; 93(12):1481-6. PubMed ID: 15194017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lowering cholesterol becomes easier. Combining instead of increasing dosage].
    MMW Fortschr Med; 2003 Jan; 145(3-4):59. PubMed ID: 12619241
    [No Abstract]   [Full Text] [Related]  

  • 9. [Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
    Klose G
    MMW Fortschr Med; 2004 Jun; 146(26):14. PubMed ID: 15529683
    [No Abstract]   [Full Text] [Related]  

  • 10. [Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
    MMW Fortschr Med; 2004 Oct; 146(44):57. PubMed ID: 15566254
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism].
    MMW Fortschr Med; 2005 Jul; 147(27-28):50. PubMed ID: 16041947
    [No Abstract]   [Full Text] [Related]  

  • 12. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Campaign against arteriosclerosis. Inhibition of cholesterol absorption in the future?].
    MMW Fortschr Med; 2002 Sep; 144(35-36):50-1. PubMed ID: 12380357
    [No Abstract]   [Full Text] [Related]  

  • 14. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
    Klose G
    MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
    [No Abstract]   [Full Text] [Related]  

  • 15. [Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].
    Vogt A; Kassner U; Hostalek U; Peiter A; Steinhagen-Thiessen E
    MMW Fortschr Med; 2006 May; 148(18):41. PubMed ID: 16736688
    [No Abstract]   [Full Text] [Related]  

  • 16. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
    Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cholesterol resorption inhibition prevents high statin doses. Lipid lowering in double-pack].
    MMW Fortschr Med; 2002 Nov; 144(48):60. PubMed ID: 12532550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.